According to WHO data, the rate of premature births ranges from 4 to 6% of all deliveries and remains a significant public health issue. Preterm birth is the leading cause of death among newborns worldwide and the second most common cause of child mortality overall. Moreover, preterm babies may face negative health consequences throughout their lives. Therefore, reducing the risk of premature births, including through medication, is of utmost importance.
The Russian company "PSK Pharma" has registered the drug Atosiban PSK, which is indicated for use in pregnant women aged 18 years and older who are at risk of premature labor starting from the 24th week of pregnancy. The drug is a selective antagonist of oxytocin receptors, effectively suppressing uterine contractions, thereby reducing the likelihood of premature labor onset. The effectiveness of drugs in this class has been confirmed by numerous clinical studies as well as long-term experience.
“Atosiban helps many women maintain their pregnancies and give birth to healthy children. That’s why it’s so important that this drug be produced within our country and always available. This ensures that every woman, when indicated, can receive timely therapy without any obstacles,” emphasized Evgenia Shapiro, Director General of “PSK Pharma.”
"Atosiban PSK" is the second product in the company's portfolio in the field of obstetrics and gynecology. Previously, "PSK Pharma" obtained a registration certificate for a hormonal drug used to prevent postpartum hemorrhage, containing Carbetocin as its active ingredient.